Cite
Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?
MLA
Chakraborty, Dwaipayan Sarathi, et al. “Will Controlled Release Mebeverine Be Able to Surpass Placebo in Treatment of Diarrhoea Predominant Irritable Bowel Syndrome?” Journal of Family Medicine and Primary Care, vol. 8, no. 10, Oct. 2019, pp. 3173–78. EBSCOhost, https://doi.org/10.4103/jfmpc.jfmpc_522_19.
APA
Chakraborty, D. S., Hazra, A., Sil, A., & Pain, S. (2019). Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? Journal of Family Medicine and Primary Care, 8(10), 3173–3178. https://doi.org/10.4103/jfmpc.jfmpc_522_19
Chicago
Chakraborty, Dwaipayan Sarathi, Avijit Hazra, Amrita Sil, and Shantasil Pain. 2019. “Will Controlled Release Mebeverine Be Able to Surpass Placebo in Treatment of Diarrhoea Predominant Irritable Bowel Syndrome?” Journal of Family Medicine and Primary Care 8 (10): 3173–78. doi:10.4103/jfmpc.jfmpc_522_19.